Clinical Trials Sponsored by Gate 21
Total 537 results
-
Nutrition 21, Inc.CompletedEfficacy and Safety Study of Chromium Picolinate + Biotin on Glucose and Cholesterol Control in T2DMDiabetes Mellitus, Type 2
-
Nutrition 21, Inc.CompletedDiabetes Mellitus, Type 2United States
-
Nutrition 21, Inc.UnknownSigns and Symptoms, DigestiveUnited States
-
Ove AndersenAalborg University; Albertslund Kommune; Gate 21; Chromaviso A/SCompletedElderly Housing Residents With Frailty or DementiaDenmark
-
Laboratoire Boreaderme Inc.Ecogene 21Unknown
-
Texas A&M UniversityNutrition 21, Inc.Completed
-
Pennington Biomedical Research CenterNutrition 21, Inc.Completed
-
Daniel GaudetUltragenyx Pharmaceutical IncActive, not recruitingSafety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial HypercholesterolemiaHomozygous Familial HypercholesterolemiaCanada
-
Glostrup University Hospital, CopenhagenPhilips Healthcare; Elforsk; Albertslund Kommune; Gate 21; DTU Fotonik; VISO systems; AF Lightning and other collaboratorsCompleted
-
Nutrition 21, Inc.ALS Beauty and Personal CareRecruitingHair Thinning | Facial Skin Texture | Skin AgeingUnited States
-
Gate Neurosciences, IncCompletedMajor Depressive DisorderUnited States
-
Gate Neurosciences, IncCompleted
-
Gate Neurosciences, IncTerminatedMajor Depressive Disorder | Excessive SleepinessUnited States
-
Gate Neurosciences, IncCompleted
-
Danderyd HospitalKarolinska Institutet; The 21 healthcare regions in SwedenNot yet recruitingHeart Diseases | Obesity, Morbid | Bariatric Surgery Candidate
-
State University of New York - Upstate Medical...Nutrition 21, Inc.Terminated
-
Fate TherapeuticsRecruiting
-
Fate TherapeuticsTerminatedLymphoma, B-Cell | Chronic Lymphocytic LeukemiaUnited States
-
Fate TherapeuticsTerminatedSolid Tumor, AdultUnited States
-
Fate TherapeuticsWithdrawnFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Transformed Indolent Non-Hodgkin's Lymphoma
-
Fate TherapeuticsCompletedMelanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditionsUnited States
-
Fate TherapeuticsTerminatedHematological MalignancyUnited States
-
Fate TherapeuticsTerminatedMetabolic DisordersUnited States
-
Fate TherapeuticsTerminatedA Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic MalignanciesHematologic MalignanciesUnited States
-
Fate TherapeuticsRecruitingSystemic Lupus ErythematosusUnited States
-
Fate TherapeuticsRecruitingAdvanced Solid TumorUnited States
-
Fate TherapeuticsRecruitingLymphoma, B-Cell | Chronic Lymphocytic Leukemia | Precursor B-Cell Acute Lymphoblastic LeukemiaUnited States
-
Fate TherapeuticsTerminatedB-cell Lymphoma | Acute Myelogenous LeukemiaUnited States
-
Fate TherapeuticsTerminatedBreast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | GastroEsophageal CancerUnited States
-
Fate TherapeuticsCompletedAcute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia | Hematologic Malignancies | Acute Graft-versus-host DiseaseUnited States
-
Fate TherapeuticsCompletedChronic Lymphocytic Leukemia (CLL) | Acute Lymphoblastic Leukemia (ALL) | Non-Hodgkin's Lymphoma (NHL) | Hodgkin's Disease | Acute Myelogenous Leukemia (AML)United States
-
Fate TherapeuticsRecruitingRelapsed/Refractory B-Cell LymphomaUnited States
-
Fate TherapeuticsTerminatedMelanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumor | Small-cell Lung Cancer | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditionsUnited States
-
Fate TherapeuticsTerminatedSolid Tumor, AdultUnited States
-
Fate TherapeuticsTerminatedAcute Myeloid Leukemia | Multiple Myeloma | Myeloma | AML, AdultUnited States
-
Fate TherapeuticsTerminatedHematologic MalignanciesUnited States
-
Fate TherapeuticsCompletedMelanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | HER2 Positive Gastric Cancer | EGFR Positive Solid TumorUnited States
-
Medi-Tate Ltd.Active, not recruitingBPHFrance, Italy, Germany, Australia, Spain, Switzerland
-
Tate & LyleBioFortisCompletedHypercholesterolemiaUnited States
-
GATT Technologies BVRecruitingLiver Diseases | Gallbladder Diseases | Intraoperative Bleeding | Hemorrhage, SurgicalUnited States
-
Medi-Tate Ltd.CompletedBenign Prostatic Hyperplasia (BPH)Spain, Belgium, Italy, Switzerland, United Kingdom
-
Medi-Tate Ltd.Terminated
-
Medi-Tate Ltd.CompletedBenign Prostate Hyperplasia | Bladder Neck ObstructionIsrael
-
Medi-Tate Ltd.CompletedBenign Prostate HyperplasiaUnited States, Canada
-
Medi-Tate Ltd.TerminatedBenign Prostatic Hyperplasia (BPH)Canada, United States
-
Medi-Tate Ltd.Terminated
-
Sussex NHS Research ConsortiumUniversity of Surrey; NHS Research and Development; Lab 21, CambridgeCompleted
-
Ronald M Burch MD PhDCompletedMajor Depressive Disorder
-
Lions Gate HospitalNorth Shore Health Research FoundationCompleted